康泰生物
(300601)
| 流通市值：167.74亿 | | | 总市值：208.08亿 |
| 流通股本：9.00亿 | | | 总股本：11.17亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,392,061,330.52 | 645,202,778.57 | 2,651,715,620.99 | 2,018,201,664.48 |
| 营业收入 | 1,392,061,330.52 | 645,202,778.57 | 2,651,715,620.99 | 2,018,201,664.48 |
| 二、营业总成本 | 1,293,245,266.49 | 594,453,971.64 | 2,301,437,136.57 | 1,597,573,808.72 |
| 营业成本 | 334,785,437.74 | 171,263,111.04 | 477,417,300.48 | 334,020,470.6 |
| 税金及附加 | 18,164,074.6 | 4,074,049.56 | 30,554,872.79 | 17,464,905.54 |
| 销售费用 | 470,244,772.23 | 208,030,761.82 | 887,247,447.88 | 671,404,158.08 |
| 管理费用 | 158,520,120.14 | 83,424,298.47 | 372,139,697.78 | 244,620,221.51 |
| 研发费用 | 296,924,139.62 | 120,628,293.1 | 508,122,984.22 | 311,770,025.07 |
| 财务费用 | 14,606,722.16 | 7,033,457.65 | 25,954,833.42 | 18,294,027.92 |
| 其中:利息费用 | 58,743,920.65 | 29,490,038.16 | 124,120,956.32 | 93,082,420.87 |
| 其中:利息收入 | 44,747,850.64 | 22,823,545.17 | 98,385,328.38 | 75,170,822.53 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 58,300 | - | 1,380,868.09 | 934,768.09 |
| 加:投资收益 | 99,250.45 | - | 465,020.57 | 481,740.54 |
| 资产处置收益 | -365,901.81 | -185,216.7 | -8,415,471.25 | -13,000.28 |
| 资产减值损失(新) | -93,665,145.75 | -22,308,160.78 | -231,519,516.32 | -104,644,795.88 |
| 信用减值损失(新) | -27,804,299.61 | -7,979,260.95 | -29,476,786.93 | -37,534,638.91 |
| 其他收益 | 24,587,238.97 | 7,861,405.83 | 98,511,776.62 | 61,279,404.53 |
| 四、营业利润 | 1,725,506.28 | 28,137,574.33 | 181,224,375.2 | 341,131,333.85 |
| 加:营业外收入 | 3,704,478.84 | 719,855.74 | 4,218,032.16 | 3,793,596.9 |
| 减:营业外支出 | 5,551,907.13 | 1,888,252.63 | 35,505,427.57 | 10,463,587.4 |
| 五、利润总额 | -121,922.01 | 26,969,177.44 | 149,936,979.79 | 334,461,343.35 |
| 减:所得税费用 | -37,722,832.42 | 4,584,067.37 | -51,616,743.01 | -16,614,430.67 |
| 六、净利润 | 37,600,910.41 | 22,385,110.07 | 201,553,722.8 | 351,075,774.02 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 37,600,910.41 | 22,385,110.07 | 201,553,722.8 | 351,075,774.02 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 37,532,743.65 | 22,434,088.56 | 201,652,296.41 | 351,095,608.08 |
| 少数股东损益 | 68,166.76 | -48,978.49 | -98,573.61 | -19,834.06 |
| 扣除非经常损益后的净利润 | 18,458,600.14 | 16,909,572.3 | 245,988,837.83 | 303,635,734.21 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | 0.02 | 0.18 | 0.31 |
| (二)稀释每股收益 | 0.03 | 0.02 | 0.18 | 0.31 |
| 八、其他综合收益 | -95,966.13 | -56,881.31 | -90,939.67 | -137,744.56 |
| 归属于母公司股东的其他综合收益 | -95,966.13 | -56,881.31 | -90,939.67 | -137,744.56 |
| 九、综合收益总额 | 37,504,944.28 | 22,328,228.76 | 201,462,783.13 | 350,938,029.46 |
| 归属于母公司股东的综合收益总额 | 37,436,777.52 | 22,377,207.25 | 201,561,356.74 | 350,957,863.52 |
| 归属于少数股东的综合收益总额 | 68,166.76 | -48,978.49 | -98,573.61 | -19,834.06 |
| 公告日期 | 2025-08-22 | 2025-04-21 | 2025-04-21 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |